Home Respiratory Distress Syndrome About Surfactants About Infasurf Frequently Asked Questions Request Additional Information

Welcome to Infasurf.com

Infasurf is indicated for the PREVENTION of Respiratory Distress Syndrome (RDS) in premature infants at high risk for RDS and for the TREATMENT "rescue" of newborn infants who develop RDS. Infasurf decreases the incidence of RDS when used as prevention. When used either to prevent or treat RDS, Infasurf lowers the incidence of lung air leaks (pneumothorax, pneumomediastinum, and pulmonary interstitial emphysema) and reduces the mortality associated with RDS.

Prescribing Information
Request Additional Information
Search:

Forest Pharmaceuticals, Inc.
13600 Shoreline Drive
St. Louis, MO 63045
Tel: 314-493-7000
Tel: 800-678-1605 (toll-free number)

ONY Pharmaceuticals
1576 Sweet Home Road, Suite 114
Amherst, NY 14228
Tel: 716-636-9096
Tel: 877-274-4669 (toll-free number)

Administration of exogenous surfactants, including INFASURF, often rapidly improve oxygenation and lung compliance. Following INFASURF administration, patients should be monitored so that oxygen and ventilatory support can be modified. During dosing with INFASURF, the most common adverse reactions reported in clinical trials were cyanosis (65%), airway obstruction (39%), bradycardia (34%), and ETT reflux (21%). These events were generally transient, and not associated with serious complications. If any of these events occur, administration should be interrupted and the infant's condition stabilized.
© 2009 Forest Laboratories, Inc.
Legal Statement | Privacy Policy | Contact Us | Site Map